Devonian Health Group Inc - Asset Resilience Ratio

Latest as of July 2023: 0.00%

Devonian Health Group Inc (GSD) has an Asset Resilience Ratio of 0.00% as of July 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Devonian Health Group Inc for a breakdown of total debt and financial obligations.

Liquid Assets

CA$0.00
≈ $0.00 USD Cash + Short-term Investments

Total Assets

CA$19.18 Million
≈ $13.87 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2021–2023)

This chart shows how Devonian Health Group Inc's Asset Resilience Ratio has changed over time. See GSD net asset value for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Devonian Health Group Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Devonian Health Group Inc market cap and net worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CA$0.00 0%
Short-term Investments CA$0.00 0%
Total Liquid Assets CA$0.00 0.00%

Asset Resilience Insights

  • Limited Liquidity: Devonian Health Group Inc maintains only 0.00% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company maintains a balanced mix of cash and short-term investments.

Devonian Health Group Inc Industry Peers by Asset Resilience Ratio

Compare Devonian Health Group Inc's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 3.28%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 0.00%
Argen-X
F:1AE
Biotechnology 25.67%
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229
Biotechnology 0.21%
R&G PharmaStudies Co. Ltd. A
SHE:301333
Biotechnology 35.96%
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
Biotechnology 79.48%
Innovita Biological Technology Co. Ltd. A
SHG:688253
Biotechnology 70.49%
Sunmax Biotechnology Co Ltd
TWO:4728
Biotechnology 10.53%

Annual Asset Resilience Ratio for Devonian Health Group Inc (2021–2023)

The table below shows the annual Asset Resilience Ratio data for Devonian Health Group Inc.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2023-07-31 0.00% CA$0.00
≈ $0.00
CA$19.18 Million
≈ $13.87 Million
--
2022-07-31 23.16% CA$5.00 Million
≈ $3.62 Million
CA$21.59 Million
≈ $15.62 Million
--
2021-07-31 0.00% CA$0.00
≈ $0.00
CA$14.61 Million
≈ $10.57 Million
--
pp = percentage points

About Devonian Health Group Inc

V:GSD Canada Biotechnology
Market Cap
$20.01 Million
CA$27.66 Million CAD
Market Cap Rank
#25034 Global
#982 in Canada
Share Price
CA$10.00
Change (1 day)
-15.97%
52-Week Range
CA$0.11 - CA$14.00
All Time High
CA$14.00
About

Devonian Health Group Inc. engages in the development of botanical drugs. Its lead product candidate is Thykamine that is in phase 3 clinical trial for the treatment of Atopic dermatitis in adult population; in phase 2/3 clinical trial for Atopic dermatitis in pediatric population; in phase 2 clinical trial for HFS associated to chemotherapy; and in phase 2/3 clinical trial for Radiodermatitis as… Read more